Total Funding
62
63
Total FundingVenture - Series Unknown raised
Growth Score 62 in past quarter
-3 pts
Heat Score 63 in past quarter
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
94456
Resonant Therapeutics is a scalable tumor microenvironment platform that speeds up therapeutic & goal discovery.
- John Westwick: CEO,President and Founder
John K. Westwick: Founder, President and CEOPast Role: Odyssey Thera, President & CEO, CSO
About the Company
Resonant Therapeutics’s platform allows for the simultaneous discovery of novel targets and high affinity, functional antibodies with unprecedented speed. Using novel insights into the tumor microenvironment and the immune system, their platform identifies targets and therapeutic candidates for any patient derived tumor tissue or cell line,
including cancer stem cells. The platform is extensible to other microenvironment regulated disease. They have created a pipeline of candidates with potent, direct anti-tumor activity, initially in breast and ovarian cancers. Their antibodies are expected to work as a monotherapy or in synergistic combination with emerging immunotherapies.